Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines
CompanyDeals

Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines

Akeso's Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
CompanyDrug

Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC

BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy
CompanyDrug

BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy

AstraZeneca's Ultomiris Approved in China for Generalized Myasthenia Gravis
CompanyDrug

AstraZeneca’s Ultomiris Approved in China for Generalized Myasthenia Gravis

Zai Lab's Augtyro NDA Accepted by China's NMPA for NTRK Fusion Solid Tumors
CompanyDrug

Zai Lab’s Augtyro NDA Accepted by China’s NMPA for NTRK Fusion Solid Tumors

Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder
CompanyDrug

Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder

Dizal Pharma Secures RMB 1.796 Billion Private Placement to Advance R&D and Facilities
CompanyDeals

Dizal Pharma Secures RMB 1.796 Billion Private Placement to Advance R&D and Facilities

Bio-Thera Solutions Gains NMPA Clinical Approval for BAT7111 in Advanced Solid Tumors
CompanyDrug

Bio-Thera Solutions Gains NMPA Clinical Approval for BAT7111 in Advanced Solid Tumors

Ascentage Pharma's Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion
CompanyDrug

Ascentage Pharma’s Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion

Gan & Lee's GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes
CompanyDrug

Gan & Lee’s GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes

China's Medical Insurance Payment Reform Achieves Nationwide Coverage, Faces Challenges Ahead
Policy / Regulatory

China’s Medical Insurance Payment Reform Achieves Nationwide Coverage, Faces Challenges Ahead

Regeneron's Eylea HD Receives FDA Complete Response Letter Despite Priority Review
CompanyDrug

Regeneron’s Eylea HD Receives FDA Complete Response Letter Despite Priority Review